-+ 0.00%
-+ 0.00%
-+ 0.00%

Natera highlights ALPHA3 interim analysis showing 58.3% MRD clearance with cema-cel

PUBT·04/13/2026 12:01:59
Listen to the news
Natera highlights ALPHA3 interim analysis showing 58.3% MRD clearance with cema-cel
  • Natera highlighted positive interim futility results from Allogene’s registrational ALPHA3 trial using Natera’s CLARITY MRD assay to identify high-risk large B-cell lymphoma patients following first-line therapy.
  • Interim analysis showed cema-cel helped more patients clear residual disease versus observation, supporting potential use as consolidation to reduce relapse risk.
  • Allogene scheduled a conference call and webcast for 5:30 a.m. PT / 8:30 a.m. ET to discuss results, indicating additional details will be presented in the future.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260413928881) on April 13, 2026, and is solely responsible for the information contained therein.